Ignite Creation Date:
2024-05-06 @ 3:52 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04782622
Status:
UNKNOWN
Last Update Posted:
2021-03-04
First Post:
2021-02-23
Brief Title:
The Combination of Apatinib and Camerlizumab for Advanced Lung Cancer Patients With Muti-line Therapy
Sponsor:
The Affiliated Hospital of Qingdao University
Organization:
The Affiliated Hospital of Qingdao University
Study Overview
Official Title:
The Combination of Apatinib and Camerlizumab for Advanced Lung Cancer Patients
Status:
UNKNOWN
Status Verified Date:
2021-03
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The combination of Apatinib and Camrelizumab for progressed NSCLC patients with muti-line therapy a phaseⅠB clinical study
Brief Summary Immunotherapy has made a major progress in Lung cancerHowever challenges such as primary and acquired resistance small fraction of benefit population and lack of predictive and prognostic biomarkers even exist The overall objective response rate is lower than 20 in second line-treatment and the progression-free survival PFS is also similar to or poorer than that of conventional second-line chemotherapy Apatinib is a novel orally administered multitarget receptor tyrosine kinase inhibitor that inhibits VEGFR PDGFR FGFR c-Kit and other kinases It functions by inhibiting tumor angiogenesis and proliferative signaling pathways We would observe and analyze the effectiveness and safety of apatinib combined with Camrelizumab for advanced NSCLC after muti-line therapy to explore the synergistic effect of anti-angiogenic agents and immunotherapy
Brief Summary Immunotherapy has made a major progress in Lung cancerHowever challenges such as primary and acquired resistance small fraction of benefit population and lack of predictive and prognostic biomarkers even exist The overall objective response rate is lower than 20 in second line-treatment and the progression-free survival PFS is also similar to or poorer than that of conventional second-line chemotherapy Apatinib is a novel orally administered multitarget receptor tyrosine kinase inhibitor that inhibits VEGFR PDGFR FGFR c-Kit and other kinases It functions by inhibiting tumor angiogenesis and proliferative signaling pathways We would observe and analyze the effectiveness and safety of apatinib combined with Camrelizumab for advanced NSCLC after muti-line therapy to explore the synergistic effect of anti-angiogenic agents and immunotherapy
Detailed Description:
Enrolled patients received apatinib plus Camrelizumab treatment apatinib 250mg qd Camrelizumab 5mgkg iv d1 21day as a cycle
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None